Cytokinetics Inc (CYTK)

Name: Cytokinetics Inc (CYTK) annual fundamentals
Creator: TickerFacts
License: https://creativecommons.org/publicdomain/zero/1.0/

Build a valuation ↗↓ Download CSV

SEC name CYTOKINETICS INC · CIK 0001061983 · Nasdaq · Pharmaceutical Preparations

Sector Manufacturing
Fiscal year ends Dec 31

For the year ended 2025-12-31, Cytokinetics Inc reported revenue of $88.04M. Revenue grew 376.6% from the prior annual period. Over the twelve months to 2026-06-30, revenue was $67.67M.

Key ratios (year ended 2025-12-31)

-695.4%

Operating margin

-891.6%

Net margin

376.6%

Revenue growth (YoY)

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form 4 (ownership change) · 2026-10-20

Headquarters locality: South San Francisco · View on map

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

The first column covers the twelve months to 2026-06-30 from the latest quarterly report: flows are the last fiscal year plus this year to date minus the same months a year earlier, and balances are as of that date. Per-share figures are annual only.

Period ended	TTM to 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31
Revenue	$67.67M	$88.04M	$18.47M	$7.53M	$94.59M	$70.43M	$55.83M	$26.87M	$31.50M	$13.37M	$106.41M
R&D Expense	n/a	$416.03M	$339.41M	$330.12M	$240.81M	$159.94M	$96.95M	$86.12M	$89.14M	$90.30M	$59.90M
Operating Income	-$707.91M	-$612.26M	-$536.25M	-$496.20M	-$324.20M	-$186.31M	-$93.94M	-$98.87M	-$88.92M	-$113.40M	$18.69M
Depreciation & Amortization	$12.55M	$10.12M	$9.53M	$11.89M	$5.81M	$2.28M	$1.83M	$1.29M	$1.24M	$1.92M	$741.0K
EBITDA	-$695.36M	-$602.13M	-$526.72M	-$484.31M	-$318.39M	-$184.04M	-$92.11M	-$97.57M	-$87.68M	-$111.48M	$19.43M
Net Income	-$894.00M	-$784.96M	-$589.53M	-$526.24M	-$388.95M	-$215.31M	-$127.29M	-$121.69M	-$106.29M	-$127.79M	$16.45M
EPS (Diluted)	n/a	-$6.54	-$5.26	-$5.45	-$4.33	-$2.80	-$1.97	n/a	n/a	-$2.59	$0.39
Total Assets	$1.92B	$1.42B	$1.40B	$824.32M	$1.01B	$841.32M	$533.80M	$289.81M	$211.18M	$294.81M	$170.14M
Total Liabilities	$2.10B	$2.08B	$1.54B	$1.21B	$1.12B	$597.46M	$420.42M	$300.75M	$185.24M	$184.97M	$75.78M
Long-Term Debt	n/a	n/a	$619.52M	$639.27M	$649.56M	n/a	n/a	n/a	$42.41M	$31.78M	$29.88M
Shareholders' Equity	-$173.49M	-$659.62M	-$135.37M	-$386.32M	-$107.90M	$243.86M	$113.38M	-$10.94M	$25.93M	$109.84M	$94.36M
Cash & Equivalents	$255.27M	$122.52M	$94.86M	$113.02M	$65.58M	$112.67M	$82.98M	$36.43M	$42.26M	$125.21M	$66.87M
Operating Cash Flow	-$555.45M	-$510.01M	-$395.89M	-$414.33M	-$299.52M	-$142.52M	$8.94M	-$90.91M	-$101.22M	-$101.76M	$36.98M
Capital Expenditures	$25.26M	$24.81M	$3.91M	$1.42M	$11.34M	$48.87M	$11.05M	$2.62M	$889.0K	$2.88M	$1.60M
Free Cash Flow	-$580.72M	-$534.82M	-$399.80M	-$415.75M	-$310.85M	-$191.39M	-$2.11M	-$93.53M	-$102.10M	-$104.64M	$35.39M
Shares Outstanding	n/a	122.94M	118.21M	101.64M	94.83M	84.80M	71.02M	59.17M	54.72M	53.96M	40.65M
Weighted Average Diluted Shares	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	49.40M	42.56M
EPS (Basic)	n/a	-$6.54	-$5.26	-$5.45	-$4.33	-$2.80	-$1.97	n/a	n/a	-$2.59	$0.41

Price chart

Chart and quotes by TradingView. Exchange coverage and delays vary.

Open chart on TradingView